Follow Slashdot stories on Twitter

 



Forgot your password?
typodupeerror

Submission Summary: 0 pending, 3 declined, 5 accepted (8 total, 62.50% accepted)

Medicine

Submission + - Merck's Drug Propecia Causing Sexual Dysfunction 2

zaxios writes: "Merck — the pharmaceutical giant previously featured on Slashdot for drawing up a 'hit list' of doctors that criticized its drug Vioxx, and creating a fake medical journal to endorse its products — is embroiled in a new scandal. USA Today is reporting on two new studies that show that Propecia, Merck's $250 million prescription medication for baldness, can make men irreversibly impotent. Lawsuits have been filed in the United States and Canada from men claiming to have permanently lost their sexual function after taking the drug. All this is reminiscent of Merck's difficulties with Vioxx, a once $2.5 billion a year drug withdrawn from the market in 2004, after a study showed it doubled the risk of heart attack and stroke in users. That led to a $4.85 billion settlement by Merck for personal injury claims."
Linux Business

Submission + - Dvorak: Is Microsoft Going to Start a Linux War?

zaxios writes: "John C. Dvorak has weighed in on the recent Novell-Microsoft pact. Among his insights: "Microsoft has been leery of doing too much with Linux because of all the weirdness with the licenses and the possibility that one false move would make a Microsoft product public domain at worst, or subject to the GPL at best." But now, "the idea is to create some sort of code that is jammed into Linux and whose sole purpose is to let some proprietary code run under Linux without actually 'touching' Linux in any way that would subject the proprietary code to the GPL." According to Dvorak, it's only a matter of time before Linux is "cracked" by Microsoft, meaning Microsoft figures out a way to run proprietary code on it. I hope Microsoft shares this discovery with VMware, Adobe, Sun, nVidia, et al."

Slashdot Top Deals

"Well, social relevance is a schtick, like mysteries, social relevance, science fiction..." -- Art Spiegelman

Working...